Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Production & Manufacturing
Manufacturing
Return to: PBR Home | Production & Manufacturing | Manufacturing

BiologicsMD enters into manufacturing contract with Cytovance

PBR Staff Writer Published 13 June 2012

BiologicsMD has entered into a manufacturing contract with Cytovance Biologics to continue development of BiologicMD's osteoporosis medication, PTH-CBD.

The agreement will focus on developing the manufacturing platform for PTH-CBD, that will allow BiologicsMD to conduct Phase I studies.

BiologicsMD president Paul Mlakar said Cytovance expertise will play a key role in accelerating the development of the compound that will hopefully improve the lives of the millions of individuals who suffer from osteoporosis.

BiologicsMD is developing a new prescription osteoporosis medication called PTH-CBD, which promises five times the efficacy of available bisphosphonate treatments with fewer side effects.

Cytovance Biologics president and chief executive officer Darren Head said, "Our experienced staff and state-of-the-art facilities are prepared to deliver the highest quality of manufacturing services for successful completion of this clinical milestone for the PTH-CBD program."

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.